HYPERION DEFI, INC.
HYPDNasdaq
$2.74
↓ -0.4%Jul 17 close · end-of-day
Price
1Y↓ -82.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$34.8M
Enterprise Value
$27.4M
P/E
—
P/S
33.3
P/B
0.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$1.0M
Net Income (TTM)
-$33.0M
Free Cash Flow (TTM)
—
Gross Margin
70.9%
Operating Margin
-3351.7%
Net Margin
—
ROE
—
ROIC
-54.0%
Debt / Equity
—
Net Cash
$7.4M
Return 1Y
-82.7%
Company profile
Eyenovia, Inc. engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. Its product candidates include MicroLine, MicroPine and MydCombi.
- CEO
- Michael M. Rowe
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- New York
- Website
- eyenovia.com
Management & directors
- Jung HyunsuChief Investment Officer
- Knox David R.Chief Financial Officer
- Rubenstein RobertGeneral Counsel
Roles derived from SEC Form 4 filings.
Earnings
HYPD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$244,271.00↑ +1559.4%
Diluted EPS$0.26↓ -116.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.0M | $14.0M | — | $3,787.00 | $57,336.00 | $813,455.00 |
| Gross profit | $1.2M | $12.4M | — | -$12,218.00 | -$3.9M | $510,165.00 |
| Operating income | -$19.8M | -$13.0M | -$26.9M | -$25.4M | -$48.7M | -$46.7M |
| Net income | -$19.8M | -$12.8M | -$28.0M | -$27.3M | -$49.8M | -$45.3M |
| Diluted EPS | -$0.94 | -$0.49 | -$0.83 | -$53.15 | -$59.81 | -$9.40 |
| Operating cash flow | -$6.4M | -$20.9M | -$25.1M | -$23.8M | -$30.1M | -$14.8M |
| Free cash flow | -$6.6M | -$22.1M | -$25.6M | -$26.7M | -$30.3M | — |
| Gross margin | 60.0% | 88.6% | — | -322.6% | -6749.5% | 62.7% |
| Operating margin | -989.5% | -93.0% | — | -670885.8% | -85004.6% | -5743.5% |
| Net margin | -988.5% | -91.3% | — | -719859.9% | -86888.6% | -5570.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22,625.00 | $1,625.00 | $28,093.00 | $14,720.00 | $0.00 | $302,506.00 | $496,229.00 | $244,271.00 |
| Gross profit | -$467,736.00 | -$130,897.00 | -$3.1M | $14,672.00 | $0.00 | $302,506.00 | $192,987.00 | $244,271.00 |
| Operating income | -$11.7M | -$7.3M | -$19.5M | -$3.0M | -$8.4M | $4.4M | -$39.8M | $8.7M |
| Net income | -$11.1M | -$7.9M | -$20.0M | -$3.5M | -$8.7M | $6.6M | -$39.8M | $8.8M |
| Diluted EPS | -$16.65 | -$9.07 | -$15.34 | -$1.59 | -$2.50 | $0.05 | -$5.36 | $0.26 |
| Operating cash flow | -$8.2M | -$5.9M | -$6.1M | -$4.4M | -$3.4M | -$2.8M | -$4.1M | -$4.2M |
| Free cash flow | -$8.2M | -$5.9M | -$6.1M | — | — | — | — | — |
| Gross margin | -2067.3% | -8055.2% | -10939.5% | 99.7% | — | 100.0% | 38.9% | 100.0% |
| Operating margin | -51661.2% | -451195.5% | -69238.4% | -20588.9% | — | 1463.8% | -8013.5% | 3574.8% |
| Net margin | -48856.1% | -485406.3% | -71031.1% | -23665.3% | — | 2190.2% | -8013.6% | 3619.2% |
Company news
Jun 22, 2026
Jun 18, 2026
May 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | GELTZEILER MICHAEL S | Award | 58,917 | $0.00 | $0.00 | filing |
| 2026-06-30 | Strahlman Ellen R | Award | 58,917 | $0.00 | $0.00 | filing |
| 2026-06-30 | JACOBSON RACHEL | Award | 58,917 | $0.00 | $0.00 | filing |
| 2026-06-30 | Walters Happy David | Award | 58,917 | $0.00 | $0.00 | filing |
| 2026-06-02 | Jung Hyunsu· See Remarks | Buy | 500 | $3.68 | $1,840.00 | filing |
| 2026-06-02 | Jung Hyunsu· See Remarks | Buy | 500 | $3.64 | $1,820.00 | filing |
| 2026-06-01 | Jung Hyunsu· See Remarks | Buy | 5,000 | $3.66 | $18,300.00 | filing |
| 2026-06-01 | Jung Hyunsu· See Remarks | Buy | 2,000 | $3.81 | $7,620.00 | filing |
| 2026-05-27 | Jung Hyunsu· See Remarks | Tax withholding | 40,000 | $0.00 | $0.00 | filing |
| 2026-03-30 | Knox David R.· Chief Financial Officer | Tax withholding | 20,831 | $0.00 | $0.00 | filing |
| 2026-01-12 | Rubenstein Robert· General Counsel | Award | 75,000 | $0.00 | $0.00 | filing |
| 2025-12-31 | Knox David R.· Chief Financial Officer | Buy | 27,950 | $3.59 | $100,340.50 | filing |
| 2025-12-29 | Strahlman Ellen R | Buy | 12,112 | $3.60 | $43,603.20 | filing |
| 2025-12-29 | Strahlman Ellen R | Buy | 11,856 | $3.61 | $42,800.16 | filing |
| 2025-12-29 | Jung Hyunsu· See Remarks | Tax withholding | 82,324 | $0.00 | $0.00 | filing |
| 2025-12-26 | Strahlman Ellen R | Buy | 3,601 | $3.86 | $13,910.66 | filing |
| 2025-12-26 | Strahlman Ellen R | Buy | 3,311 | $3.86 | $12,777.15 | filing |
| 2025-12-18 | Strahlman Ellen R | Buy | 19,702 | $3.14 | $61,834.73 | filing |
| 2025-12-18 | Strahlman Ellen R | Buy | 18,742 | $3.14 | $58,829.26 | filing |
| 2025-12-17 | Walters Happy David | Buy | 61,930 | $3.02 | $187,152.46 | filing |
| 2025-12-17 | GELTZEILER MICHAEL S | Buy | 30,000 | $3.01 | $90,210.00 | filing |
| 2025-09-29 | Knox David R.· Chief Financial Officer | Award | 100,000 | $0.00 | $0.00 | filing |
| 2025-09-29 | Knox David R.· Chief Financial Officer | Award | 200,000 | $0.00 | $0.00 | filing |
| 2025-09-08 | Walters Happy David | Award | 50,000 | $0.00 | $0.00 | filing |
| 2025-08-18 | Jung Hyunsu· Chief Investment Officer | Award | 1,000,000 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.